Posted by admin on Jun 9th, 2022
Sigyn Therapeutics (NASDAQ:SIGY – Get Rating) and Pulmonx (NASDAQ:LUNG – Get Rating) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.
This table compares Sigyn Therapeutics and Pulmonx’s net margins, return on equity and return on assets.
Sigyn Therapeutics has a beta of -0.92, meaning that its share price is 192% less volatile than the S&P 500. Comparatively, Pulmonx has a beta of 1.69, meaning that its share price is 69% more volatile than the S&P 500.
92.9% of Pulmonx shares are held by institutional investors. 78.5% of Sigyn Therapeutics shares are held by company insiders. Comparatively, 8.5% of Pulmonx shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
This is a summary of current ratings and recommmendations for Sigyn Therapeutics and Pulmonx, as reported by MarketBeat.
Sigyn Therapeutics presently has a consensus target price of $0.93, suggesting a potential upside of 171.14%. Pulmonx has a consensus target price of $31.17, suggesting a potential upside of 61.74%. Given Sigyn Therapeutics’ stronger consensus rating and higher possible upside, equities research analysts clearly believe Sigyn Therapeutics is more favorable than Pulmonx.
This table compares Sigyn Therapeutics and Pulmonx’s top-line revenue, earnings per share and valuation.
Sigyn Therapeutics has higher earnings, but lower revenue than Pulmonx.
Pulmonx beats Sigyn Therapeutics on 6 of the 11 factors compared between the two stocks.
About Sigyn Therapeutics (Get Rating)
Sigyn Therapeutics, Inc. operates as a development-stage therapeutic technology company. It offers Sigyn Therapy, a blood purification technology to overcome the limitations of previous drugs and devices to treat life-threatening inflammatory disorders, including sepsis, the cause of hospital deaths. The company also engages in evaluating the Sigyn Therapy to address CytoVesicles that transport inflammatory cytokine cargos throughout the bloodstream. Sigyn Therapeutics, Inc. is headquartered in San Diego, California.
Pulmonx Corporation, a medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also provides StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.
Receive News & Ratings for Sigyn Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sigyn Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
Analyzing DoubleDown Interactive (NASDAQ:DDI) and LiveVox (NASDAQ:LVOX)
Scotiabank Increases Dollarama (OTCMKTS:DLMAF) Price Target to C$81.00